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Expression and diagnostic utility of anti-cyclic citrullinated peptide 
antibodies in juvenile idiopathic arthritis 
 
INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is a clinically 
heterogeneous autoimmune disease of unknown 
cause, characterized by chronic, inflammatory 
changes of the joints, as for rheumatoid arthritis 
(RA) in adults.1 The diagnosis of JIA resembles RA 
because it is mostly dependent on clinical features 
of the disease after excluding infection and other 
inflammatory diseases.2 Moreover, it is very 
difficult to establish the diagnosis of JIA, especially 
at the early stage of the disease, since the clinical 
symptoms are often not characteristic.3, 4 
The clinical diagnosis of RA can be supported 
only by limited serological markers with confirmed 
serological value; one of them is IgM class 
rheumatoid factor (IgM-RF). However, contrary to 
RA, in JIA especially at the onset of the disease 
IgM-RF is found only in low numbers.3-5 
Recent studies have demonstrated anti-
citrullinated protein/peptide antibodies (ACPA) 
which include anti-CCP antibodies, have high 
specificity for RA, and are now included in the 
revised diagnostic criteria for RA.6 Although anti-
CCP antibodies have only been recently discovered 
to have a diagnostic value for RA, with a specificity 
of 96-100%7 and a sensitivity of 40-85%8 However, 
their diagnostic value for JIA is still debatable with 
a relatively few studies have shown the diagnostic 
efficacy of anti-CCP in JIA.9 
This study sought to investigate the prevalence 
and diagnostic utility of anti-CCP antibodies in 
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children with JIA and its relationship to clinical, 




This cross-sectional controlled study was carried 
out in the Departments of Pediatrics and 
Rheumatology and Rehabilitation of El-Minia 
University Hospital. A sample of forty children and 
adolescents (13 males, 27 females) with JIA was 
recruited in the study. Their ages ranged from 3.5 to 
18 years with a mean ± SD of 12.3 ± 4.4. They 
were already diagnosed cases of JIA fulfilling the 
1997 International League Against Rheumatism 
(ILAR) classification criteria.5 The patients were 
consecutively enrolled in the study during their 
regular visits to the outpatient clinic. They 
comprised 10 oligoarticular, 26 polyarticular, and 
four systemic onset JIA cases.  Patients diagnosed 
with other autoimmune diseases, chronic diseases, 
or malignancies were excluded.  
Onset and duration of JIA disease and 
demographic variables were recorded. Clinical 
examination of the patients included the status of 
arthritis and systemic manifestations including 
fever, rash, and visceral involvement. Active 
disease was defined by the presence of joint 
swelling or limitation of movement with either pain 
on movement or tenderness. Non-active disease 
(remission) was defined by the absence of joint 
swelling or limitation of movement with no pain on 
movement or tenderness.10  
The control group comprised 35 clinically 
healthy children and adolescents (15 males and 20 
females) who were consecutively recruited at their 
visits to Children's University Hospital Clinics for 
minor traumatic causes. Their age ranged from 6 to 
18 years with a mean of 12.1±3.6. 
An informed consent was obtained from the 
parents or care givers according to the medical 
ethical regulations and the protocol was approved 
by the Ethics’ Committee of the Department of 
Pediatrics, Children's Hospital Minia University. 
Methods 
 The following laboratory tests were done for both 
patients and controls: 
i. Erythrocyte sedimentation rate (ESR), 
measured by the Westergren method. 
ii. Serum IgM rheumatoid factor (RF), measured 
by latex agglutination test. 
iii. Serum anti-cyclic citrullinated peptide (Anti-
CCP) antibodies:  
A blood sample (2-3 ml) was collected, 
centrifuged and sera were stored at -20˚C until 
assayed. Samples were tested without knowing the 
clinical details of patients and were done using the 
Quanta lite ™CCP IgG ELISA according to the 
manufacturer’s instructions, a semi-quantitative 
enzyme-linked immunosorbent assay for the 
detection of IgG Anti-CCP IgG antibodies in 
patient sera (the antigen). According to the 
manufacturer, anti-CCP antibodies considered 
positive when its serum level is 20 units/ml or 
more.  
 Radiographic assessment: a postero-anterior plain 
X-ray of the hands and wrists were obtained to 
detect radiological joint damage (defined as joint 
narrowing and/or erosions). The radiological data 
were collected from their files, nearly from the 
same time of blood collection from the patients. 
The control subjects underwent serum Anti-CCP 
antibody and RF measurement and their samples 
were assayed in the same setting as the patients. 
They were also subjected to ESR assessment. 
Children with family history of autoimmune illness 
were excluded from this group. 
Statistical analysis 
Data entry and analysis were performed using the 
SPSS (Statistical Package for Social Science) for 
windows version 11.5. Categorical data were 
presented as numbers and percentage (%) and were 
compared using the Chi Square and Fisher's exact 
tests as appropriate. Numerical data were presented 
by mean and standard deviation (mean ± SD) and 
were compared using the t-student test. Correlations 
between anti-CCP antibody and clinical parameters 
were attempted by the Spearman’s rank correlation 
coefficient test. The diagnostic value of anti-CCP 
antibodies was determined by calculation of 
sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV). P 




The female gender was more represented in the 
studied sample with female: male ratio of 2.1:1, 
(p<0.05). Age was compatible between the patients 
and controls. The ESR was significantly higher in 
the JIA patients than control group (p <0.0001).  
The RF positivity was 7.5% (3 cases) in the 
patients’ group versus 0/35 in control group; 
however the difference did not reach statistical 
significance (p=0.24). The number of positive anti-
CCP patients was 8/40 (20%) compared to 0/35 
(0.0%) in the control group (p=0.01); Table 1. 
Among the 27 patients with polyarticular JIA, 8 
patients had positive anti-CCP antibodies of whom 
7 patients (87.5%) suffered the polyarticular 
subtype and only one patient (12.5%) had 
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oligoarticular JIA. Similarly, radiographic erosive 
arthritis was detected in 8 patients, 7 (87.5%) had 
polyarticular and only one patient (12.5%) had 
oligoarticular JIA. Three patients in the 
polyarticular JIA subtype were identified with both 
positive RF and Anti-CCP antibody; all of whom 
had radiographic erosive arthritis (Table 2). 
Significant positive correlations could be elicited 
between the anti-CCP antibodies and disease 
duration (r=0.59), number of tender joints (r=0.68), 
and number of swollen joints (r=0.39); (Table 3). 
Table 4 reveals a significant difference in age 
according to anti-CCP positivity in the JIA patients. 
The disease duration and number of tender and 
swollen joints showed a similar variation. RF 
positivity was also significantly higher in anti-CCP 
positive cases. 
Calculation of the diagnostic performance of 
anti-CCP antibodies in JIA showed a sensitivity of 
20% and specificity of 100%; the positive 
predictive (PPV) and negative predictive (NPV) 
values NPV were100%, and 52.2%, respectively. 
 
 
Table 1. Demographic and laboratory data of the studied sample. 
Variables JIA patients (n = 40) 
Control 
(n = 35) P 
Age (yr) mean ± SD 12.3 ± 4.4 12.1 ± 3.6 0.86 
Female /male 27/13 23/12 0.02 
ESR (mm) mean ± SD 40.2 ± 27.4 10.6 ± 5.1 0.0001 
Positive RF (%) 3/40 (7.5%) 0/35 (0%) 0.24 
Positive Anti-CCP (n) 8/40 (20%) 0/35 0.01* 




Table 2. Variation of the disease duration, RF positivity, and radiographic joint affection 
according to JIA subtypes. 
Variables Oligoarticular JIA (n=10) 
Polyarticular JIA 
(n=26) 
Systemic Onset JIA 
(n=4) 
Disease duration (mo) 22.6 ± 19.8 36.5 ± 35 16.2 ± 3.5 
Positive RF (%) 0 (0%) 3 (11.5%) 0 (0%) 
Radiographic joint erosion 1 (10%) 7 (26.9%) 0 (0%) 




Table 3. Correlations between anti-CCP antibodies and clinical data. 
Variables r p 
Disease duration (mo) 0.59 0.0001 
Tender joints (number) 0.68 0.001 
Swollen joints (number) 0.39 0.01 




Table 4. Variation of clinical data and RF results according to anti-CCP status. 
Variables Anti-CCP positive (n=8) 
Anti-CCP negative 
(n=32) P 
Disease duration (mo): mean ± SD 62.1±44.1 23.7±20.9 0.001 
Tender joints: median (range) 10 (3-14) 2 (0-5) 0.002 
Swollen joints: median (range) 4 (1-6) 2 (0-4) 0.01 
Positive RF 3 0 0.01 
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DISCUSSION 
Juvenile idiopathic arthritis has clinical features 
which greatly differ from those of RA.1,11 Since a 
highly specific and sensitive laboratory marker of 
JIA has not yet been found, the diagnosis of JIA is 
mainly dependent on the clinical manifestations. 
Although RF has a high sensitivity in the diagnosis 
of RA (but with a low specificity), it has a low 
sensitivity in the diagnosis of JIA8. Anti-CCP are 
auto-antibodies which are being increasingly used 
to aid in early diagnosis of RA as they have been 
found to be highly specific (96-98%) in the 
diagnosis of RA.12  
Among our series, anti-CCP was detected in 
8/40 (20%). A limited number of studies with 
controversial results are available as far as the 
diagnostic value of anti-CCP antibodies in JIA is 
concerned. Van Rossum et al.13 reported 10 cases 
(14%) with positive anti-CCP among 71 children 
with JIA. Similarly, prevalence rates of 20.8% and 
23.1% of anti-CCP antibodies in JIA were reported 
by Habib et al14 and Gupta et al15 respectively. A 
more recent study by Tebo16 et al has also detected 
prevalence of 14.3% in children with JIA (OR 8.2, 
p <0.01). 
On the other hand, several studies have not 
shown usefulness of anti CCP antibodies either in 
diagnosis or prognosis of JIA. Avcin et al17 and 
Kasapcopur et al18 reported that anti-CCP 
antibodies were rare in patients with JIA (1.8% out 
of 109 and 2% out of 122 respectively). Similarly, 
Machado et al19, found that only one out of 45 JIA 
patients was positive for anti-CCP.  Avcin et al17 
speculated that the low rate of positivity may be due 
to the fact that their study was a multicenter one, 
with no consistent inclusion criteria other than 
clinical diagnosis. In addition, the time of serum 
collection in correlation with state of disease 
activity might have influenced the anti-CCP 
antibody expression. The divergence also of the 
results in various researches could be due to the use 
of different ELISA kits in the assay. The validity of 
our results is definitely limited by the sample size. 
In the current study, as anticipated, most cases 
positive for anti-CCP [7 of 8 (87.5%)] had 
polyarticular JIA and demonstrated radiographic 
erosive arthritis. Only one patient (12.5%) with 
oligoarticular JIA developed serum anti-CCP 
antibodies. Moreover, all RF-positive polyarticular 
JIA children in the present study had anti-CCP 
antibody positivity. Our results are in line with 
those reported by van Rossum et al13 who reported 
anti-CCP antibody positivity in 73% of RF positive 
polyarticular JIA and radiological damage was 
observed on the radiographs of 8 out of 10 (80%) 
anti-CCP positive patients. A relevant study also 
reported that 7 of 8 (87.5%) patients with RF IgM 
positive polyarticular JIA had anti-CCP antibodies 
in their sera. Also, 11 out of 19 (58%) patients with 
joints erosions had significant levels of anti-CCP 
antibodies compared to only 12% of patients 
without erosions.15    
Over again, a group of investigators from 
China20 reported anti-CCP antibody positive rates of 
31.25%, 14.8% and 0%, in polyarticular, 
oligoarticular, and systemic-onset JIA respectively. 
Anti-CCP antibodies seem to play an important role 
in the pathogenesis of RA inflammation, because 
RA patients with anti-CCP antibodies have a more 
aggressive disease course with joint erosion and 
damage. Citrullinated proteins might be targets of 
the local immune response in patients with RA and 
may perpetuate a persistent state of synovitis 
leading to joint destruction.21 
Another notable finding in our series is the 
positive correlation between anti-CCP antibodies 
and disease duration, and number of joints showing 
signs of arthritis. This observation was supported 
by a significant difference between anti-CCP 
antibody positive and negative JIA patients in terms 
of the number of swollen and tender joints. These 
findings might indicate that anti-CCP antibodies 
can be good markers of disease activity. This is in 
accordance with the findings of Lipinska J et al12 
who reported that serum anti-CCP concentrations 
were significantly higher in children with higher 
activity of the rheumatoid process (p=0.014; 
R=0.25).   
Recently, a relevant study by Omar and 
coworkers22 has also concluded that Anti-CCP 
antibodies were prevalent among a group of 
Egyptian children and adolescents JIA patients with 
polyarticular patterns compared to other disease 
patterns (F=4.845, P=0.012) with significant 
correlation with radiological damage as assessed by 
Sharp/Van der Heijde Score (r=0.457, P<0.001). 
It is suggested that JIA with both RF and anti-
CCP positive antibodies could be an indicator of 
more aggressive and severe disease that leads to 
joint damage and disability. Thus their simultaneous 
presence help in putting more aggressive 
immunosuppressive treatment plans such as the use 
of biological therapy.23   Bacos et at24 has recently 
shown that pediatric JIA patients with high anti-
CCP antibodies and older onset of disease 
frequently can have continuous inflammatory 
activity during adult life and may need further care 
in the adult rheumatology clinic. Another recently 
published study by Gilliam et al25 has also reported 
JIA patients with joint damage were positive for 
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various combinations of anti-citrullinated 
antibodies, with IgG anti-CCP and anti-citrullinated 
fibrinogen antibody positivity demonstrated in 7/20 
(35%) patients with joint damage  
The overall diagnostic performance of anti-CCP 
antibodies in JIA in the present study has shown 
low sensitivity (20%), high specificity (100%), high 
PPV (100%), and moderate NPV (54.2%). This 
comes in concordance with a couple of previous 
studies.13,20 The high specificity, was mostly 
demonstrated in RF-positive polyarthritis, may be 
explained by the fact that this particular form of the 
disease phenotypically resembles rheumatoid 
arthritis (RA) in adults, and might actually 
represent the childhood onset of RA.1  
The present study has the following limitations 
including the limited size of the studied sample and 
being a cross sectional study; it does not explore the 
relationship between the levels of anti-CCP 
antibodies and treatment and/or long term outcome. 
Also, the time of sampling for anti-CCP assay was 
not studied in relation to an objective activity 
scoring methodology.  
In conclusion, anti-CCP antibodies can be 
detected with low rates but high specificity in 
patients with JIA being more frequently detected in 
the polyarticular subtype. The anti-CCP positivity 
was positively correlated to RF positivity, disease 
severity and radiographic joint erosion. It could 
therefore be a useful serologic marker of severity 
and may guide optimum treatment decision-making 
in order to reduce joint damage and disability.  
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